In this report, we describe the complete 34 794 base pair genomic sequence of the human adenovirus serotype 35 (Ad35) Holden strain. The viral genome exhibits a compact organization similar to other adenoviral serotypes, with overlapping genes on both strands. In all, 47 open reading frames (ORFs) were identified, including early (E1, 2, 3, 4) and late (L1, 2, 3, 4, 5) regions conserved among the adenoviridae family. In addition, 14 ORFs were identified that do not encode known adenoviral genes. Comparison of the predicted translational products of the conserved genes with those of other adenoviruses revealed that Ad35 has high homology to Ad7, Ad3, Ad21, Ad17, and simian Ads25. Based on the complete Ad35 DNA sequence, E3-, E1-, and E1/E3-deleted Ad35-based vector systems were developed.
Introduction
Adenoviruses are large, double-stranded, linear DNA viruses that have been isolated from numerous mammalian species. The human adenoviruses constitute a large family with at least 51 identified serotypes, 1 which are classified in seven subgroups on the basis of hemagglutination or DNA homology (as determined by restriction mapping and hybridization). Such homology is above 50% within a subgroup, and less than 25% between subgroups. 2 The sequence variations in different subgroups reflect their distinct biology and pathophysiology, including factors such as differing tropisms, high-or low-affinity receptor usage, and intracellular trafficking pathways. [3] [4] [5] The easy manipulation of the genome, the high-titer production of recombinant adenoviruses, and the infectivity of diverse cell types have made adenoviruses very useful gene transfer vectors, especially for vaccine and gene therapy studies. Complete adenoviral sequences have been reported, including Ad2, 6 Ad5, 7 Ad12, 8 Ad17, 9 and Ad40. 10 Partial DNA sequences of all human subtypes, and other mammal and bird subtypes, have been reported in literature and GenBank databases. These data are essential for studying the biology of unknown adenoviruses as well as for generating new types of recombinant adenoviruses.
Although the majority of adenoviral vectors are based on Ad5 or Ad2 serotypes, it is likely that the low prevalence of preexisting neutralizing antibodies and the varying tropisms of uncommon adenoviral serotypes may make these more suitable for development as gene transfer vectors. Adenovirus type 35 (Ad35) Holden strain, belonging to adenovirus subgroup B, was isolated in 1973 from the lungs and kidney of a 61-year old woman. 11 This unique adenovirus is isolated most frequently from immunosuppressed individuals such as AIDS patients and transplant recipients, and it has a tropism for the urinary tract.
12-14 Ad35 is not widespread in the general population. 14, 15 Although the partial sequence of the Ad35 genome covering the E3 region has been published, 16 in this report we describe the complete 34 794 base pair (bp) sequence of Ad35, the analysis of the open reading frames (ORFs), and the comparison with other previously characterized adenoviral serotypes. Furthermore, we have developed E3-, E1-, and E1/E3-deleted Ad35-based vectors and verified their ability to efficiently infect both human and rhesus macaque dendritic cells (rhDC). Our findings support the use of Ad35-based vectors as alternative gene transfer vehicles for DNA-based vaccine development and gene therapy applications.
Results

Nucleotide sequence and gene organization
We determined the complete 34 794 bp genomic sequence of Ad35 (GenBank accession number AY128640). Both strands were sequenced using different primers. Analysis of the complete sequence by the Open Reading Frame Finder from NCBI identified 47 ORFs, each at least 300 bp in length, with 33 of the ORFs conserved among the adenovirus family. The additional 14 ORFs, which have no homologies with any previously reported adenoviral genes, were named ORF1-14. Figure  1 illustrates the organization of the ORFs in the three possible translational reading frames for both strands. As expected, the Ad35 genes are compact, similar to other adenoviruses, and genes are encoded on both complementary strands.
Translational reading frames and comparison of the protein sequences
The predicted translational features of all ORFs greater than 300 bp in size are shown in Table 1 . The putative splicing sites of the E1A, E2B, and L4 regions were identified and will need to be confirmed by experimental mapping. All of the unknown ORFs (ORF1-14) distributed in conserved adenoviral regions are shown in Table  1 ; these include ORF1 found in the E1 and pIX region, ORF2-11 in the E2 and IVa2 regions, ORF12, 13 in the E3 region, and ORF14 in the E4 region. The primary aminoacid sequences of the Ad35 genes were compared with the corresponding sequences of other adenoviral serotypes ( Table 2 ). The sequence and organization of the E3 region has been published 16 and was not included in our analysis. Homology analysis revealed that Ad35 has the highest similarity to Ad3, Ad7, Ad21, and simian adenovirus Ads25.
Construction of an E3-deleted recombinant Ad35 vector
An E3-deleted Ad35 vector was generated by intermolecular homologous recombination of Ad35 genomic DNA with a plasmid containing enhanced yellow fluorescent protein (pAd35EYFP) after cotransfection into HEK293 cells (Figure 2a ). The pAd35EYFP contains 308 bp of E3 sequence (position 26888-27199), followed by a lox P site to facilitate subsequent generation of Ad35 E3-or E1/E3-deleted vectors, an expression cassette encoding EYFP gene under the control of a CMV promoter, and the Ad35 sequence spanning position 30405 to the right inverted terminal repeat (ITR). This linearized plasmid was cotransfected into HEK293 cells with Ad35 genomic DNA that was pretreated with Exonuclease III (ExoIII) to remove the single strand of both 3 0 terminal ends. The rationale of this strategy is the fact that adenoviral DNA cannot rescue infectious adenovirus without the terminal protein when removed up to 2500 bp of the 3 0 terminus by ExoIII; 17 following recombination, the DNA replicates and is repaired through a panhandle replication mechanism. 18 The expression of EYFP was used to screen for the presence of recombinant virus (Ad35E3/EYFP) using fluorescence microscopy. As an loxP sequence has been inserted into the E3 region, E3-deleted recombinant virus can be generated by cotransfecting the designed E3 shuttle plasmid pAd35E3 and treated parent viral DNA of Ad35E3/EYFP into the CRE8 cell (Figure 2b ).
Establishment of E1-deleted Ad35 packaging cell lines
To generate an Ad35 E1-deleted vector, E1-complementing cell lines were established. We constructed two expression plasmids each encoding either the E1A or the E1B gene of Ad35, and transfected them into the CRE8 cell line, resulting in E1A, E1B, and E1A/E1B packaging cell lines. After cotransfecting the pAd35E1/Red shuttle vector with ExoIII-treated Ad35 genomic DNA, we found that E1A cell lines did not transcomplement E1-deleted virus rescue, whereas the E1A/E1B and E1B cell lines did. No significant differences were found between the E1B and E1A/E1B cell lines in terms of plaqueforming capacity (data not shown). Thus, cell line establishment was focused on the E1B gene. Plasmids expressing the E1B gene under the EF-1a promoter or the EF-1a promoter plus the E1B native promoter were compared. The latter displayed greater efficiency for plaque formation (data not shown). Next, 158 individual Figure 1 Gene organization of Ad35. The gene layout of Ad35 was obtained using NCBI Open Reading Frame Finder. Three possible translational reading frames for both strands are illustrated. ORFs larger than 300 bp were analyzed in this report. The known adenovirus genes were labeled as used by other adenoviruses. Unknown ORFs were named ORF1-14 according to the appearance from left to right.
Ad35-based gene transfer vector development
W Gao et al colonies that stably expressed the E1B gene under EF-1a and the native promoter were isolated, expanded, and screened for plaque-forming efficiency by infection of Ad35E1/Red viruses. As shown in Figure 3 , the CRE35G3 clone appeared to be the most potent in plaque-forming efficiency.
Construction of an E1-deleted recombinant Ad35 vector
E1-deleted Ad35 virus was generated via homologous recombination by cotransfecting the pAd35E1/Red shuttle plasmid with ExoIII-treated Ad35 genomic DNA into the E1B-based CRE8 cell line (Figure 4a ). With regard to Ad35 E1-deleted vector growth on CRE35G3, cosmic-like plaque formation is the same as Ad5, but plaque opening begins at the head of the cosmic, then slowly enlarges at the periphery of the opening without a clear cytopathic effect until the late stage of infection, although viruses are still being propagated in packaging cells. This particular feature was also found in wild-type Ad35E3/EYFP virus. This may be explained by the different pH requirements for membrane lysis by Ad35 and Ad5.
Construction of an E1-/E3-deleted recombinant Ad35-based vector
Ad35E1-/E3-deleted virus was generated by cotransfection of pAd35E1 with ExoIII-treated Ad35E3/EYFP genomic DNA into CRE35G3 cells ( Figure 4b ). The resultant virus Ad35E1/E3/EYFP has 2512 bp of E1 deleted (E1A and most of the E1B gene) and 3205 bp of E3 deleted (all of E3). As an loxP sequence has been introduced into the E3 region, we can conveniently generate E1-/E3-deleted recombinant virus by cotransfecting the designed E3 shuttle plasmid pAd35E3 and treated parent viral DNA (Ad35E1/E3/EYFP) into the packaging cell line CRE35G3 ( Figure 4c ).
Production of the Ad35 E1-deleted vector by transient E1B gene expression
Since the E1B gene alone can efficiently support E1-deleted Ad35 virus production on HEK293 cells, we hypothesized that transient transfection of pEF/nE1B (E1B gene under EF-1a and E1B native promoter control) into HEK293 cells could lead to propagation of the E1-deleted Ad35 virus. At 8 h after transfection with varying amounts of pEF/nE1B, HEK293 cells were infected with Ad35E1/Red at a multiplicity of infection (MOI) ¼10. The ratio of 3 mg of plasmid to 6 Â 10 6 of HEK293 cells was deemed optimal ( Figure 5 ).
Evaluation of the emergence of RCA
To determine if replication-competent adenovirus (RCA) arises in the Ad35-based vector system, the Ad35E1/Red recombinant virus was propagated on CRE35G3 cells (15 passages). The resultant viruses were used to infect A549 cells. No RCA was detected on A549 cells.
Evaluation of the transduction efficiency of the Ad35 vector on dendritic cells
Using the Ad35E3/EYFP virus, we evaluated the infection efficiency of Ad35 using human dendritic cells (hDC). On day 5 of culture, hDC were transduced with Ad35E3/EYFP at MOI¼10, 50, 100, and 250. Efficient Ad35-mediated gene transfer into hDC was evaluated by fluorescence microscopy and by flow cytometric analysis. Mean fluorescence intensity in hDC infected with Ad35E3/EYFP revealed that more than 95% of the cells expressed EYFP after infection at an MOI¼10 or greater (Figure 6a, b) . Also, rhDC were transduced with Ad35E3/EYFP at an MOI¼100. The fluorescence intensity in rhDC showed that more than 97% of rhDC expressed EYFP (Figure 6c ).
Discussion
Vectors based on the human adenovirus subgroup C (ie types 2 and 5) have been used extensively in preclinical and clinical studies of gene therapy. 19 These recombinant adenoviral vectors have been rendered replicationdefective by the deletion of E1 sequences and grown in E1-complementing cell lines such as HEK293. To generate even more disabled vectors, multiple essential genes (such as E4 and E2) or even all viral genes have been deleted. [20] [21] [22] [23] However, an important limitation of the use of Ad2-and Ad5-based vectors for human applications is that many individuals are immune to these viruses because of previous infection. A manifestation of existing immunity to the virus is B-cell activation, which leads to persistent neutralizing antibodies that block vector uptake in vivo and diminish transduction. Selective modification of the hypervariable regions of the hexon diminishes type-specific cross-neutralization in vitro without avoiding neutralization in vivo. 24, 25 As a way to circumvent problems related to existing immunity, it is possible to use a vector based upon an adenoviral serotype of low frequency. Ad35, belonging to the serotype B group, is uncommon, and neutralizing antibodies to it are not prevalent in the population. In this report, we describe the development of several novel and versatile Ad35-based vector systems.
As a first step towards the development of novel Ad35-based vectors for gene transfer and therapy, we sequenced and characterized the human Ad35 (Holden strain) genome. Complete sequence analysis revealed a structure similar to that of most human adenoviruses. The closest known adenoviral relatives to Ad35 are the subgroup B adenovirus types 3, 7, 11, 17, 21, and simian Ads25. In addition, we detected 14 ORFs, most of which are believed to be noncoding regions, although some of them have the potential to encode Ad35 proteins with novel functions. Based on the Ad35 sequence analysis, we generated a recombinant E3-deleted Ad35 encoding the EYFP gene. In this wild-type E3-deleted virus, we also introduced a loxP sequence upstream of the EYFP expression cassette to facilitate the generation of recombinant virus through Cre/lox recombination. The Ad35E3/EYFP can efficiently infect and propagate on HEK293, A549, and other human tumor cell lines (data not shown). Ad35E3/EYFP genomic DNA was used to generate several E3-deleted recombinant viruses for use as live SIV/HIV vaccines in rhesus macaques (manuscript in preparation). Also, the Ad35E3/EYFP vector served as a good marker virus for the quantitative E1A 262R  77  77  77  52  49  38  35  36  E1A 231R  76  75  74  50  46  33  32  31  E1B 214R  88  58  55  42  50  46  46  50  E1B 494R  84  69  44  43  52  44  44  53  pIX  88  76  45  47 L3 pVI  72  63  63  58  56  68  L3 pII  86  84  90  83  83  78  75  78  78  L3 23k  89  76  74  75  75  73  L4 100 K  62  61  61  59  L4 22 K  33  34  L4 33 K  62  50  41  41  L4 pVIII  93  80  94  90  77  80  80  82  L5 pIV  59  55  94  26  24  25  19  22  25  26 Ad35-based gene transfer vector development W Gao et al analysis of neutralizing antibodies in different populations (manuscript in preparation). Finally, the Ad35E3/ EYFP virus proved to be very stable; even after storage for more than 1 year at À801C, viral infectivity was not decreased as compared with the fresh preparation (data not shown).
Our goal is to develop a new vector suitable for in vivo DNA vaccination that is as efficient as Ad5-based vectors in inducing cellular immune responses, but is not neutralized by pre-existing immunity. Deletion of the E1 genes is crucial for vector safety. To design a strategy for the production of E1-deleted Ad35 vectors suitable for preclinical and clinical studies, several issues merit consideration. First, an E1-expressing cell line is needed for both efficient vector generation and production. Second, the cell line and the vector must be designed to avoid the emergence of RCA. Our study showed that the E1 gene of Ad5 present in the HEK293 cell line Ad35-based gene transfer vector development W Gao et al cannot efficiently compensate for the E1 function of Ad35; thus, to enable production of the E1-deleted vector and to avoid RCA, we established E1A, E1A/E1B, and E1B expression cell lines derived from the parent CRE8 cell line. The plasmid pAd35E1/Red cotransfected with ExoIII-treated Ad35 genomic DNA made it possible to observe 'red plaque' formation on these cell lines under a fluorescence microscope. Plaque-formation efficiency on these cell lines indicated that the E1A gene alone did not support plaque formation, but the cell lines containing the E1A/E1B and E1B genes did. Surprisingly, E1B cell lines efficiently supported E1-deleted virus growth on HEK293 cells. We compared the effect on plaque formation between constructs encoding the E1B gene with or without the native promoter; results showed that E1B with the native promoter was more efficient for E1-deleted virus production. Furthermore, CRE35G3 was found to be the most efficient line among the 158 colonies.
In the Ad35E3 vector, 3205 bp were deleted (9% of Ad35), and in the Ad35E1 vector, 2512 bp were deleted (7% of Ad35), including E1A and most of E1B, which should not be expressed in the E1-deleted vector. The pIX protein, which integrates into the virion capsid and stabilizes the virus, is required, especially when the viral genome is 45% of the wild-type genome; thus, an intact pIX gene with its native promoter remained in the E1-deleted virus. In the Ad35E1/E3 vector, 5717 bp were deleted (16% of Ad35).
In Ad5-or Ad2-based vector production, the appearance of RCA is of concern. It is difficult to control recombination between the vector DNA and the left arm of Ad5 in HEK293-derived cells, and RCA inevitably occurs in viral culture. However, in the cell line described here, no RCA was detected, even after 15 passages. It is believed that recombination between the Ad5 E1 region in HEK293 cells and the Ad35 E1 region, both of which have low homology, is rare, and the E1B ORF in HEK293 cells is unlikely to recombine with the E1-deleted Ad35 vector, thus rendering the Ad35E1-deleted virus RCA-free. In this case, the Ad35-based vector has a greater safety advantage than an Ad5-based vector.
We also developed a process for the production of the Ad35 E1-deleted vector on HEK293 cells by transient transfection of a single plasmid, pEF/nPE1B. Vector production is as efficient as in CRE35G3 cells. This development could lead to propagation of the E1-deleted Ad35 vector in Ad5 E1-based cell lines already approved by the FDA for clinical-grade adenovirus production.
Dendritic cells represent the most potent antigenpresenting cells, able to induce a strong Th1 immune response. We analyzed the gene transduction efficiency of an Ad35-based vector in both human and rhesus macaque DC. Given that infection of hDC at an MOI¼10 
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W Gao et al resulted in more than 95% of the cells being transfected; our Ad35-based vector appears to be more efficient at infecting DC than the Ad5-based vector. In summary, we report herein the full genomic sequence and gene organization analysis of human adenovirus serotype 35, and describe our development of E3-, E1-, and E1/E3-deleted Ad35-based vector systems. We believe that our novel Ad35-based vectors will be potent and versatile tools for DNA vaccine development and gene therapy.
Materials and methods
Ad35 DNA preparation
The Ad35 Holden strain was obtained from ATCC (ATCC number VR-718). The virus was propagated on HEK293 cells and subsequently purified by two rounds of cesium chloride gradient centrifugation. Viral DNA was extracted from purified virions as described by Pettersson & Sambrook 26 and used for sequencing and E3-deleted recombinant Ad35 vector generation.
Sequence strategy and analysis
The genomic sequence of Ad35 was determined using the chain termination method/genome walking approach and nucleotide primers (19-23 bases in length). The design of the primary sequencing primers was based on the published partial Ad35 nucleotide sequences. 16 Sequencing was performed on a 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) using the BigDye Terminator V3.1 cycle sequencing kit (Applied Biosystems). Both strands were sequenced at least two times. The obtained raw sequences were analyzed using several software programs. Sequencert (version 3.1.2, Gene Codes Corporation, Ann Arbor, MI, USA) was used to assemble the complete Ad35 DNA sequence; proofreading was performed manually on the raw data. Open Reading Frame Finder from NCBI (www.ncbi.nlm.nih.-gov/gorf/gorf.html) was used to detect the ORFs, deduce the amino-acid sequences, and perform sequence comparisons. Extensive analyses were carried out to assess the percentage of primary amino-acid sequence similarity between Ad35 and other adenoviruses. Wise2 (www.sanger.ac.uk/wise2/genewiseform.shtml) was used to detect the potential splicing sites for E1A, pIVa2, and L4 33K genes.
Ad35 E3-deleted plasmid construction
A 308 bp PCR fragment of E3 sequence (from position 26 888 to 27 199) included a LoxP site was cloned into plasmid pEYFP-N1 (Clontech, Palo Alto, CA, USA) at a unique AseI site (upstream of the CMV promoter). The DNA fragment to be inserted was obtained by PCR using the forward primer 5 0 -CGT TTA TTA ATC TGA TGA TCA GAG GCC GAG-3 0 and reverse primer 5 0 -ACT GGA TTA ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA TCA ATC GTA GCC GTC CAC TG-3 0 . The AseI sites within the primers are shown in italics and the LoxP sequence is underlined. The Ad35 fragment from 30405 bp to the end of the right ITR was obtained by EcoRV digestion of Ad35 genomic DNA and inserted in the recombinant plasmid at an AflII-blunted site. The resulting plasmid (pAd35EYFP) was linearized by SfiI and purified by phenol/chloroform extraction.
Generation of the E3-deleted Ad35 vector by homologous recombination
The Ad35 DNA was digested by ExoIII (1 U/mg of Ad35 DNA) for 40 min at 371C and extracted using phenol/ chloroform. The ExoIII-treated Ad35 DNA (5 mg) and 5 mg of the SfiI-linearized pAd35E3/EYFP plasmid were cotransfected into HEK293 cells by calcium phosphate precipitation in 60-mm plates. At 7 days post-transfection, resultant plaques were picked and the virus was released by three freeze/thaw cycles. E3-deleted virus (Ad35E3/EYFP) was prepared by infection of HEK293 cells, followed by purification on cesium chloride density gradients and subsequent dialysis against storage buffer (20 mM Tris pH 8, 75 mM NaCl, 2 mM MgCl 2 , 5% D ( þ ) Trehalose, and 0.0025% Tween 80). The recombinant Ad35E3/EYFP DNA was extracted, and the identity of the recombinant was confirmed by sequence analysis. The adenoviral titer was determined by optical densitometry; virus was stored at À801C until the time of use.
Ad35 E3 shuttle plasmid construction
To efficiently generate recombinant virus using Cre/lox recombination in CRE8 cells, 27 an E3 shuttle plasmid was constructed. The EcoRV fragment from position 30405 to the end of the right ITR of Ad35 was cloned into pZero/ blunt (Invitrogen, Carlsbad, CA, USA). A PCR fragment that included the left ITR sequence, the loxP sequence, and a CMV-MCS-polyA fragment was cloned at the HindIII and BamHI sites upstream of the EcoRV fragment. Two EcoRV sites were engineered to flank the L-ITRloxP-expression cassette-R-ITR for linearization of the cloned fragment and, thus, efficient generation of E3 or E1/E3 recombinant virus. The E3 shuttle plasmid was named pAd35E3.
Ad35 E1 shuttle plasmid construction
The plasmid pZero/blunt (Invitrogen) was used for the construction of the E1 shuttle plasmid. Briefly, a PCR fragment from the left ITR to position 561 of Ad35 was cloned into pZero/blunt. A second fragment from position 3074 to 7935 was cut from Ad35 genomic DNA and inserted downstream of the first fragment. Subsequently, 2512 bp were deleted, including the entire E1A region and most of the E1B region. The ORF of the pIX gene and its promoter remained intact. To facilitate gene cloning, a unique SwaI site was introduced between position 561 and 3074. The E1 shuttle plasmid was named pAd35E1. A marker gene DsRed2 (red fluorescent protein) expression cassette containing the CMV promoter, the DsRed2 gene, and poly A from pDsRed2 was cloned into the E1 shuttle plasmid at SwaI site. The resulting plasmid (pAd35E1/Red) was used for the generation of E1-deleted recombinant adenovirus.
Establishment of packaging cell lines
The PCR fragments of Ad35 E1A(569-1441) was cloned into pIRES/puro (Clontech) to generate pIRES/E1A; the E1B ORF(1621-3400) and E1B promoter region plus ORF(1538-4300) were cloned into pEF/Topo (Invitrogen) to generate pEF/E1B and pEF/nE1B, respectively. CRE8 cells were used to establish cell lines compensating for E1-deleted Ad35 virus growth and providing the Cre recombinase for Cre/lox recombination. Plasmids (5 mg) were transfected or cotransfected using calcium Ad35-based gene transfer vector development W Gao et al phosphate precipitation in 60-mm plates. Cells were selected in blasticidin (10 mg/ml) and/or puromycin (2 mg/ml) containing complete Dulbecco's Modified Eagle Medium (DMEM). E1A cell lines, E1A/E1B cell lines, and E1B cell lines were used for making E1-deleted recombinant virus by recombination. Cell lines supporting plaque formation were further colony-isolated, expanded, and screened for plaque-forming efficiency. Briefly, E1B cell lines or A549 cells were infected with Ad35E1/Red over a range of serial dilutions and overlaid with top agar after 20 h. Plaques were counted using a fluorescence microscope on day 5 postinfection. Relative plaquing efficiencies (RPE) were calculated by standardizing as 100% the cell line with the greatest plaque number and comparing all other values to it.
E1-deleted Ad35 vector generation
The plasmid pAd35E1/Red was linearized with EcoRI and cotransfected with ExoIII-treated Ad35 genomic DNA into CRE8-based Ad35E1A, E1B, or E1A/E1B cell lines by calcium phosphate precipitation. Plaque formation was observed using a fluorescence microscope. The E1-deleted virus (Ad35E1/Red) was used for cell screening as described above.
E1-/E3-deleted Ad35 vector generation
The colony-isolated CRE8-based Ad35E1B cell line (CRE359G3) was used to generate the E1-/E3-deleted Ad35 vector. Briefly, pAd35E1 (without the expression cassette) was linearized with EcoRI and cotransfected with ExoIII-treated Ad35E3/EYFP genomic DNA into CRE359G3 by calcium phosphate precipitation. Plaques were isolated. Virus was propagated on CRE359G3 as described above.
Production of E1-deleted Ad35 recombinant virus by transient expression of E1B genes
HEK293 cells were transfected with the pEF/nE1B plasmid at varying ratios of 0, 1, 3, and 5 mg/6 Â 10 6 of cells on 12-well plates. The medium was changed after 8 h. Cells were infected with Ad35E1/Red at MOI¼10 and overlaid with top agar after 20 h. Plaques were counted using a fluorescence microscope on day 5 postinfection. RPE were calculated by standardizing as 100% the ratio of 3 mg of plasmid per 6 Â 10 6 of HEK293 cells with the greatest plaque number and comparing all other ratios to it. The concentration giving the optimum RPE was used to transfect HEK293 cells on 150-mm plates. Cells were harvested after 96 h, and virus purification was performed as described above.
Detection of RCA in E1-deleted recombinant virus preparations
Ad35E1/Red virus was passaged on CRE359G3 cells 15 times and purified by CsCl gradient centrifugation. A total of 1 Â 10 8 plaque-forming units of each testing virus was diluted in 100 ml of DMEM and aliquoted into 150-mm plates of A549 cells (1 Â 10 7 cells per plate). Cells were harvested 14 days later and lysed in DMEM by three rounds of freezing/thawing. In all, 30% of the total cell lysate was used to infect A549 cells as described above. RCA was examined using fluorescence and light microscopy to observe plaque formation and cytopathic effects.
Transduction efficiency assay
Human and rhesus macaque dendritic cells were isolated from Ficoll-Hypaque-purified peripheral blood mononuclear cells. Briefly, PBMCs were washed, resuspended in AIM-V medium (1 Â 10 7 cells/ml), and allowed to differentially adhere to a 75-cm 2 tissue culture flask for 90 min at 371C. The nonadherent cells were removed by gentle rinsing, and the remaining adherent cells were cultured in AIM-V supplemented with 1000 U/ml of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) (both from Schering-Plough, Kenilworth, NJ, USA) for 5 days. On day 5, DC were harvested with cold HBSS, centrifuged at 600 g for 5 min and carefully resuspended in 100 ml of HBSS. DC were infected with Ad35E3/EYFP at an MOI¼10-250 in HBSS for 90 min at room temperature, cultured in DC medium for 48 h, and analyzed by flow cytometry and fluorescence microscopy to quantify the efficiency of transduction.
